Lumosa Therapeutics Co (ROCO:6535) COGS-to-Revenue : 0.42 (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Lumosa Therapeutics Co COGS-to-Revenue?

Lumosa Therapeutics Co's Cost of Goods Sold for the three months ended in Mar. 2025 was NT$3.71 Mil. Its Revenue for the three months ended in Mar. 2025 was NT$8.90 Mil.

Lumosa Therapeutics Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.42.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lumosa Therapeutics Co's Gross Margin % for the three months ended in Mar. 2025 was 58.34%.

Lumosa Therapeutics Co COGS-to-Revenue Historical Data

The historical data trend for Lumosa Therapeutics Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumosa Therapeutics Co COGS-to-Revenue Chart

Lumosa Therapeutics Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.39

0.43

0.45

0.27

0.55

Lumosa Therapeutics Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.69	0.41	0.57	0.57	0.42

Lumosa Therapeutics Co COGS-to-Revenue Calculation

Lumosa Therapeutics Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	21.441	/	39.154
	=	0.55

Lumosa Therapeutics Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3.706	/	8.896
	=	0.42

Lumosa Therapeutics Co (ROCO:6535) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lumosa Therapeutics Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	3.706 / 8.896
	=	58.34 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Lumosa Therapeutics Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lumosa Therapeutics Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumosa Therapeutics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumosa Therapeutics Co Ltd (ROCO:6535) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503

Website

https://www.lumosa.com.tw

Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods.

Lumosa Therapeutics Co Headlines

No Headlines